Non-Modulating CLEC9A Binding Agents for Antigen Presentation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current cancer therapies face challenges in effectively targeting dendritic cells to enhance anti-tumor immunity due to cancer immune evasion, while MS treatments are limited by incomplete efficacy and side effects, highlighting the need for improved therapeutic and diagnostic agents that can recruit and activate these cells without modulating Clec9A signaling.

Innovation Solution

Development of Clec9A binding agents, such as single-domain antibodies (VHHs), which specifically bind to Clec9A without functional modulation, allowing recruitment of immune cells to tumor sites and enhancing antigen presentation for effective immune responses.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional cancer therapies are used to enhance anti-tumor immunity, then immune response is activated, but cancer immune evasion and toxicity reduce treatment efficacy and patient tolerance

Engineering Contradiction:

Improvetreatment efficacyVSAvoidtoxicity and immune evasion

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses dendritic cells as intermediary agents to bridge the gap between tumor antigens and T cells. The binding agent recruits dendritic cells to the tumor microenvironment, where they naturally process and present antigens, thereby indirectly activating anti-tumor immunity without directly exposing the system to toxic conventional therapies or allowing cancer immune evasion mechanisms to interfere with direct cell-cell contact

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If current pharmacological treatments for MS are used to modify or suppress the immune system, then neurological relapses are reduced, but incomplete efficacy and side effects limit treatment outcomes

Engineering Contradiction:

Improveefficacy in reducing relapsesVSAvoidside effects and incomplete efficacy

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The binding agent exhibits local quality by specifically targeting dendritic cells at the site of interest (tumor microenvironment or inflamed tissue) rather than systemically suppressing or modifying the entire immune system. This localized action allows for effective immune modulation at the disease site while preserving overall immune function and reducing systemic side effects

Inventive Principle:

Principle #3Local quality

3Productivity

If binding agents are designed to recruit Clec9A-expressing cells to a site of interest, then cell recruitment is enhanced, but Clec9A signaling may be modulated or neutralized

Engineering Contradiction:

Improvecell recruitment efficiencyVSAvoidClec9A signaling function

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The binding agent extracts only the cell recruitment function of Clec9A interaction while leaving the signaling function intact. By designing the binding agent to bind to Clec9A in a manner that facilitates dendritic cell recruitment to the tumor microenvironment without blocking the Clec9A-mediated signaling pathways, the patent separates these two functions and preserves the beneficial signaling while achieving enhanced recruitment

Inventive Principle:

Principle #2Taking out (Extraction)

Data Source

PatentUS12453770B2CLEC9A binding agents

Publication Date: 2025.10.28 ORIONIS BIOSCIENCES BV

AI summary

The present invention relates, in part, to agents that bind C-type lectin domain containing 9A (Clec9A) and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the Clec9A binding agents and their use in the treatment of various diseases.